Skip to main content

Table 2 ORR across tumor type and individual biomarker result

From: Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitors

Disease Test PD-L1 result Responders Non-responders Total ORR
Melanoma IHC TPS ≥1% 10 8 18 55.60%
< 1% 22 36 58 37.90%
RNA-seq High 8 3 11 72.70%
Moderate & low 24 41 65 46.20%
NSCLC IHC TPS ≥1% 10 28 38 26.30%
< 1% 7 43 50 14.00%
IHC TPS ≥50% 8 11 19 42.10%
< 50% 9 60 69 13.00%
RNA-seq High 10 25 35 28.60%
Moderate & low 7 46 53 11.90%
RCC IHC TPS ≥1% 2 3 5 40.00%
< 1% 5 35 40 12.50%
IHC ICS ≥1% 1 3 4 25.00%
< 1% 6 35 41 14.60%
RNA-seq High 3 6 9 33.30%
Moderate & low 4 32 36 8.30%